Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

被引：98

作者：

Sawyers, CL ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Dept Med, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Mol Pharmacol, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, Dept Urol, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

CANCER CELL | 2002年 / 1卷 / 05期

关键词：

D O I：

10.1016/S1535-6108(02)00080-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.

引用

页码：413 / 415

页数：3

共 26 条

[21] Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study [J].

Sawyers, CL ;

Hochhaus, A ;

Feldman, E ;

Goldman, JM ;

Miller, CB ;

Ottmann, OG ;

Schiffer, CA ;

Talpaz, M ;

Guilhot, F ;

Deininger, MWN ;

Fischer, T ;

O'Brien, SG ;

Stone, RM ;

Gambacorti-Passerini, CB ;

Russell, NH ;

Reiffers, JJ ;

Shea, TC ;

Chapuis, B ;

Coutre, S ;

Tura, S ;

Morra, E ;

Larson, RA ;

Saven, A ;

Peschel, C ;

Gratwohl, A ;

Mandelli, F ;

Ben-Am, M ;

Gathmann, I ;

Capdeville, R ;

Paquette, RL ;

Druker, BJ .

BLOOD, 2002, 99 (10) :3530-3539

[22] Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase [J].

Schindler, T ;

Bornmann, W ;

Pellicena, P ;

Miller, WT ;

Clarkson, B ;

Kuriyan, J .

SCIENCE, 2000, 289 (5486) :1938-1942

[23] Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study [J].

Talpaz, M ;

Silver, RT ;

Druker, BJ ;

Goldman, JM ;

Gambacorti-Passerini, C ;

Guilhot, F ;

Schiffer, CA ;

Fischer, T ;

Deininger, MWN ;

Lennard, AL ;

Hochhaus, A ;

Ottmann, OG ;

Gratwohl, A ;

Baccarani, M ;

Stone, R ;

Tura, S ;

Mahon, FX ;

Fernandes-Reese, S ;

Gathmann, I ;

Capdeville, R ;

Kantarjian, HM ;

Sawyers, CL .

BLOOD, 2002, 99 (06) :1928-1937

[24] BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study [J].

von Bubnoff, N ;

Schneller, F ;

Peschel, C ;

Duyster, J .

LANCET, 2002, 359 (9305) :487-491

[25] Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies [J].

Yamamoto, Y ;

Kiyoi, H ;

Nakano, Y ;

Suzuki, R ;

Kodera, Y ;

Miyawaki, S ;

Asou, N ;

Kuriyama, K ;

Yagasaki, F ;

Shimazaki, C ;

Akiyama, H ;

Saito, K ;

Nishimura, M ;

Motoji, T ;

Shinagawa, K ;

Takeshita, A ;

Saito, H ;

Ueda, R ;

Ohno, R ;

Naoe, T .

BLOOD, 2001, 97 (08) :2434-2439

[26]

YEE KWH, 2001, AM SOC HEM 43 ANN M

← 1 2 3 →